Type 1 diabetes update: Immune therapy, screening, and new technology
Recent advancements in type 1 diabetes care include the FDA approval of the immune therapy Teplizumab and expanded screening recommendations for high-risk individuals. Pediatric endocrinologists are also increasingly adopting automated insulin delivery technology as the standard of care.
Why it matters
These developments represent a significant shift in managing type 1 diabetes, offering new hope for delaying disease progression and improving patient outcomes.
Three recent developments in type 1 diabetes care were particularly relevant for pediatricians, according to Brittany S. Bruggeman, MD: an immune therapy approved for clinical disease, expanded screening recommendations, and automated insulin delivery (AID) technology becoming the standard of care.
Bruggeman, a pediatric endocrinologist and type 1 diabetes physician scientist at the University of Florida in Gainesville, was discussing the developments in an interview with Contemporary Pediatrics during the American Academy of Pediatrics 2026 National Conference & Exhibition.
Teplizumab (Tzield) was approved by the FDA in 2026 for clinical type 1 diabetes, marking the first immune therapy available at the onset of symptomatic disease.¹ Because patients retained functioning beta cells at diagnosis, the therapy prolonged endogenous insulin secretion, according to Bruggeman.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in